Mr. Madison commented, “I am pleased to join AMAG during this very important time in the company's development. There are a multitude of patients who suffer from the devastating effects of iron deficiency anemia and are in need of effective new treatment options. Over the next 12 months, we will look to significantly increase Feraheme adoption in the CKD market, while we plan and prepare for the potential launch for the broader IDA population, pending regulatory approval. I look forward to working with our team to bring forward innovative solutions for patients and caregivers alike."Mr. Madison is an active Board member of, and a member of the Operations Committee with, Kidney Care Partners, a Washington DC based organization that is focused on legislative, regulatory and public policy issues related to patients with CKD. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst.
AMAG Pharmaceuticals Appoints Greg Madison As Chief Commercial Officer
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.